Pharmaceutical intermediates
Asciminib hydrochloride Intermediates
6 pharmaceutical intermediates for Asciminib hydrochloride. Indication: Chronic Myelogenous Leukemia.
About Asciminib hydrochloride
- Originator
- Novartis Pharmaceuticals Corp
- Indication
- Chronic Myelogenous Leukemia
- Approved Date
- 04/18/2024
- NCE Patent
- 10/29/2026
- DS/DP
- 05/13/2033
Available intermediates
6 intermediates currently listed for Asciminib hydrochloride. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (R)-3-Pyrrolidinol | 2799-21-5 | / | / |
| Methyl 5-bromo-6-chloronicotinate | 78686-77-8 | / | / |
| 1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester | 903550-26-5 | / | / |
| 4-(Chlorodifluoromethoxy)aniline | 39065-95-7 | / | / |
| 5-Bromo-6-chloronicotinic acid | 29241-62-1 | / | / |
| 4-[chloro(difluoro)methoxy]-{N}-methylaniline | 1217004-66-4 | / | / |
Building toward Asciminib hydrochloride?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →